High-dose cyclophosphamide without stem-cell rescue for refractory CIDP

T. H. Brannagan, A. Pradhan, T. Heiman-Patterson, A. C. Winkelman, M. J. Styler, D. L. Topolsky, P. A. Crilley, R. J. Schwartzman, I. Brodsky, D. E. Gladstone

Research output: Contribution to journalArticlepeer-review

Abstract

Four patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who were refractory to conventional treatment were treated with high-dose cyclophosphamide (200 mg/kg over 4 days). All improved in functional status and muscle strength. Nerve conduction studies improved in three of four. Other immunomodulatory medications have been discontinued. High-dose cyclophosphamide can be given safely to patients with CIDP and patients with disease persistence after standard therapy may have a response that lasts for over 3 years and results in long-term disease remission.

Original languageEnglish (US)
Pages (from-to)1856-1858
Number of pages3
JournalNeurology
Volume58
Issue number12
DOIs
StatePublished - Jun 25 2002
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'High-dose cyclophosphamide without stem-cell rescue for refractory CIDP'. Together they form a unique fingerprint.

Cite this